Comparison of motor fluctuations and L-dopa-induced dyskinesias in patients with familial and sporadic Parkinson's disease

European Journal of Neurology

Volumn 11, Issue 2, 2004, Pages 115-119

  Papapetropoulos, S ^a,b   Argyriou, A A ^a   Ellul, J ^a   Chroni, E ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Complications of therapy; Dyskinesias; Familial Parkinson's disease; Motor fluctuations

Indexed keywords

LEVODOPA;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DYSKINESIA; FAMILIAL DISEASE; HEREDITY; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; MOTOR DYSFUNCTION; PARKINSON DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; RATING SCALE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; CHI-SQUARE DISTRIBUTION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR SKILLS DISORDERS; PARKINSON DISEASE; STATISTICS, NONPARAMETRIC;

EID: 1242337417     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1351-5101.2003.00727.x     Document Type: Article

References (25)

1. Ahlskog JE, Muenter MD (2001). Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448-458.
2. Barbeau A (1976). Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol 33:333-338.
3. Barbeau A (1980). High-level therapy in severely akinetic parkinsonism patients: twelve years later. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson's Disease: Current Progress, Problems and Management. Elsevier, Amsterdam, pp. 229-239.
4. Bonifati V, Fabrizio E, Vanacore N et al. (1995). Familial Parkinson's disease: a clinical genetic analysis. Can J Neurol Sci 22:272-279.
5. Brannan T, Yahr MD (1995). Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 37:95-98.
6. Fahn S, Elton R, Members of the UPDRS Development Committee (1987). Unified Parkinson's disease rating scale. In: Recent Developments in Parkinson's Disease, Vol II. Macmillan Healthcare Information, New Jersey, pp. 153-163.
7. Gouider-Khouja N, Belal S, Hamida MB et al. (2000). Clinical and genetic study of familial Parkinson's disease in Tunisia. Neurology 54:1603-1609.
8. Hoehn MM, Yahr MD (1967). Parkinsonism: onset, progression and mortality. Neurology 17:427-442.
9. Hughes AJ, Ben-Shlomo Y, Daniel SE et al. (1992). What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42:1142-1146.
10. Kitada T, Asakawa S, Hattori N et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism [see comments]. Nature 392:605-608.
11. Kostic V, Przedborski S, Flaster E et al. (1991). Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 41:202-205.
12. Lang AE, Lozano AM (1998). Parkinson's disease. Second of two parts. N Engl J Med 339:1130-1143.
13. Lees AJ, Stern GM (1981). Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 44:1020-1023.
14. Lesser RP, Fahn S, Snider SR et al. (1979). Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29:1253-1260.
15. Lyons KE, Hubble JP, Troster AI et al. (1998). Gender differences in Parkinson's disease. Clin Neuropharmacol 21:118-121.
16. Marsden CD, Parkes JD (1977). Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1:345-349.
17. Miyawaki E, Lyons K, Pahwa R et al. (1997). Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 20:523-530.
18. Papapetropoulos S, Paschalis C, Athanassiadou A et al. (2001). Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. J Neurol Neurosurg Psychiatry 70:662-665.
19. Papapetropoulos S, Paschalis C, Ellul J et al. (2002). Survival duration of Parkinson's disease patients living in Greece who carry the G209A alpha-synuclein mutation. Mov Disord 17:847-848.
20. Papapetropoulos S, Paschalis C, Athanassiadou A, Papadimitriou A, Papapetropoulos T (2003). Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece. Eur J Neurol 10:1-6.
21. Plante-Bordeneuve V, Taussig D, Thomas F et al. (1995). A clinical and genetic study of familial cases of Parkinson's disease. J Neurol Sci 133:164-172.
22. Poewe WH, Lees AJ, Stern GM et al. (1986). Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 9:430-439.
23. Polymeropoulos MH, Lavedan C, Leroy E et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease [see comments]. Science 276:2045-2047.
24. Schrag A, Quinn N (2000). Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123:2297-2305.
25. Schwab RE, England AC (1969). Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FD, ed. Third Symposium of Parkinson's Disease. Livingstone, IMI. Edinburgh, pp. 152-157.